News

Featured news

Lumos Diagnostics Reaches 50% Recruitment Milestone in FebriDx CLIA Waiver Clinical Study
2 June 2025

Lumos Diagnostics has announced that the Company has now successfully achieved 61 bacterial positive patients, representing 50% of the target of 120 bacterial positive patient results required for the study...

Lumos Secures Sixth US Medicare Reimbursement for FebriDx®
27 May 2025

Lumos has announced that it has received confirmation of Medicare reimbursement coverage for FebriDx from another Medicare Administrative Contractors (MACs), CGS Administrators...

MAY 2025 | ANALYST REPORT | More Medicare Reimbursement Coverage Secured for FebriDx
7 May 2025

MST Access Senior Analyst Chris Kallos has released an updated report on Lumos Diagnostics, maintaining a valuation of A$0.10 per share and highlighting our significant progress...

All news
Lumos Diagnostics Reaches 50% Recruitment Milestone in FebriDx CLIA Waiver Clinical Study
2 June 2025

Lumos Diagnostics has announced that the Company has now successfully achieved 61 bacterial positive patients, representing 50% of the target of 120 bacterial positive patient results required for the study...
Lumos Secures Sixth US Medicare Reimbursement for FebriDx®
27 May 2025

Lumos has announced that it has received confirmation of Medicare reimbursement coverage for FebriDx from another Medicare Administrative Contractors (MACs), CGS Administrators...
Lumos Secures Fifth US Medicare Reimbursement for FebriDx®
19 May 2025

Lumos has announced that it has received confirmation of Medicare reimbursement coverage for FebriDx from another...
Lumos Advances FebriDx® Sales with iMedical Purchase Order
14 May 2025

Lumos has today announced that it has received and shipped a purchase order for FebriDx® from iMedical, Inc. for US$126,000, representing its largest single purchase order since the test's launch.
Q3 FY25 Investor Briefing
7 May 2025

Lumos CEO and MD, Doug Ward, and CFO, Barrie Lambert, this week presented the Company's Q3 FY25 quarterly results...
MAY 2025 | ANALYST REPORT | More Medicare Reimbursement Coverage Secured for FebriDx
7 May 2025

MST Access Senior Analyst Chris Kallos has released an updated report on Lumos Diagnostics, maintaining a valuation of A$0.10 per share and highlighting our significant progress...
Stockhead | Biocurious: Lumos shines a light on the post-pandemic rapid diagnosis sector
30 April 2025

Lumos was recently featured in this insightful Stockhead article by business journalist Tim Boreham.

Quarterly Activity Statement & 4C | Period ending 31 March 2025
29 April 2025

Lumos Diagnostics (ASX:LDX) has released its quarterly report for the period ending 31 March 2025....
Lumos secures additional US Medicare reimbursement coverage for FebriDx®
23 April 2025

Lumos has announced that it has received confirmation of Medicare reimbursement coverage from two additional Medicare Administrative Contractors (MACs)...
Lumos secures US Medicare reimbursement coverage for FebriDx®
17 April 2025

Lumos has announced that it has achieved a series of important reimbursement milestones in the US...
VIDEO |1H FY25 Results Investor Briefing
5 March 2025

Lumos CEO and MD, Doug Ward, and Chief Financial Officer, Barrie Lambert, held an investor briefing this week...
Lumos Announces Expanded Scope of Work under Hologic fFN Development Agreement
3 March 2025

Lumos Diagnostics has announced an agreement to expand the scope of work under the Development Agreement...
FebriDx® Featured in Australian Doctor
14 February 2025

General practitioners (GPs) routinely assess conflicting symptoms of respiratory illness in their patients - and on the balance of available information and clinical judgement, often prescribe antibiotics on the spot...
Video | Q2 FY25 Investor webinar
5 February 2025

Lumos CEO Doug Ward and CFO Barrie Lambert present the Company's latest quarterly performance...
Lumos Diagnostics receives CPT PLA procedure code approval for FebriDx™ in the US
5 December 2024

Lumos has today announced that it has received approval from the Centers for Medicare and Medicaid Services...
Nine News Coverage
21 November 2024

Lumos' FebriDx® was featured on Channel 9 News during its prime time 6pm national bulletin last night...
Lumos Successfully Completes Retail Entitlement Offer
8 October 2024

Lumos Diagnostics has announced that it has successfully completed the retail component of its Entitlement Offer...
Lumos and BARDA to Partner to Support FebriDx® CLIA Waiver Study and Application
3 October 2024

Lumos has been awarded US$2,984,571 from the Biomedical Advanced Research and Development Authority (BARDA)...
Lumos Awarded National Contract with MediGroup for FebriDx®
25 September 2024

Lumos Diagnostics has been awarded placement of their novel POC test, FebriDx®...
Lumos Appoints Thermo Fisher Scientific as US Distributor for FebriDx®
16 September 2024

Lumos Diagnostics has signed an agreement with Fisher Healthcare, a part of Thermo Fisher Scientific...

Subscribe for Lumos news

By entering your email address you are agreeing to our Privacy Policy.

Innovation at the point-of-care

2024 Lumos Diagnostics

Quick links
Engage with us